Medication OveruseNCT07305376
Older Adults' Attitudes Towards Stopping Aspirin
A study testing Additional harm information and Less information in people with Medication Overuse, run by University of Michigan at 1 site in United States.
Trial summary
This online, survey-based experiment will include 2,400 adults who are 65 years and older (n=1,200 each from the United States and Australia). Each participant will be asked to share their opinions on a hypothetical patient scenario developed by our multidisciplinary team. Read more about this study
- Who is it for?
- Ages 65 years and olderHealthy volunteers can take part
- Conditions the study is for
- Medication Overuse
- What is being tested?
- Additional harm information and Less information
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,819 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Nov 2025to 30 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Who may be able to join
- Reside in Australia or the United States
- 65 years and older
Who cannot join
- Unable to read survey written in English
Trial locations and contacts
1 site in 1 country.
About this study
This online, survey-based experiment will include 2,400 adults who are 65 years and older (n=1,200 each from the United States and Australia). Each participant will be asked to share their opinions on a hypothetical patient scenario developed by our multidisciplinary team. This work is expected to significantly contribute to the understanding of how older adults make decisions about deprescribing medications. The long-term goal is to enhance communication between older adults and clinicians so that medication regimens are optimized and align with care preferences. These results will directly inform future research on the impact of communication choices in clinical practice.
- Conditions
- Medication Overuse
- Being tested
- Additional harm information, Less information
- Medical subject headings
- Prescription Drug Overuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Additional harm informationOther
Participants received additional information about the harm of continuing aspirin.
Less informationOther
Participants will receive less information about the risk of harms of continuing aspirin.
| Study group | Role | What they receive |
|---|---|---|
| Source of recommendation - Physician | Experimental | Participants read a hypothetical scenario where a doctor recommends stopping aspirin. Receives: Other: Additional harm information; Other: Less information |
| Source of recommendation - Pharmacist | Experimental | Participants read a hypothetical scenario where a pharmacist recommends stopping aspirin. Receives: Other: Additional harm information; Other: Less information |
| Source of information - AI | Experimental | Participants read a hypothetical scenario where artificial intelligence is used to recommend stopping aspirin. Receives: Other: Additional harm information; Other: Less information |
What is being measured
The primary outcome is the main question the study is designed to answer.
"How safe do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale
Measured: Day 1
"How helpful do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2025
- Study start10 Nov 2025
- Primary completion30 Nov 2025
- Study completion30 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medication OveruseStudies of the same condition, open and under way.
- More trials run by University of MichiganThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 2,819 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Michigan
- Sponsor type
- University, hospital or other
- Collaborators
- University of Sydney
- Responsible party
- Principal investigator, Sarah Vordenberg, University of Michigan
- Investigators
- Sarah Vordenberg, PharmD, MPH, Principal investigator, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07305376
- Sponsor's protocol ID
- HUM00280646
- Status last verified
- Nov 2025
- First submitted
- 13 Nov 2025
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Older Adults' Attitudes Towards Stopping Aspirin
- ClinicalTrials.gov ID
- NCT07305376
- Acronym / sponsor ID
- HUM00280646
- Conditions
- Medication Overuse
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,819 participants (actual)
- Lead sponsor
- University of MichiganUniversity, hospital or other
- Collaborators
- University of Sydney
- Study start
- 10 Nov 2025 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 30 Nov 2025 (actual)
- First posted
- 26 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This online, survey-based experiment will include 2,400 adults who are 65 years and older (n=1,200 each from the United States and Australia). Each participant will be asked to share their opinions on a hypothetical patient scenario developed by our multidisciplinary team. This work is expected to significantly contribute to the understanding of how older adults make decisions about deprescribing medications. The long-term goal is to enhance communication between older adults and clinicians so that medication regimens are optimized and align with care preferences. These results will directly inform future research on the impact of communication choices in clinical practice.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Source of recommendation - Physician | Experimental | Other: Additional harm information, Other: Less informationParticipants read a hypothetical scenario where a doctor recommends stopping aspirin. |
| Source of recommendation - Pharmacist | Experimental | Other: Additional harm information, Other: Less informationParticipants read a hypothetical scenario where a pharmacist recommends stopping aspirin. |
| Source of information - AI | Experimental | Other: Additional harm information, Other: Less informationParticipants read a hypothetical scenario where artificial intelligence is used to recommend stopping aspirin. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
Key inclusion criteria (2 listed)
- Reside in Australia or the United States
- 65 years and older
Key exclusion criteria (1 listed)
- Unable to read survey written in English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Additional harm informationParticipants received additional information about the harm of continuing aspirin. | Other | Source of information - AI, Source of recommendation - Pharmacist, Source of recommendation - Physician |
| Less informationParticipants will receive less information about the risk of harms of continuing aspirin. | Other | Source of information - AI, Source of recommendation - Pharmacist, Source of recommendation - Physician |
Primary outcome
"How safe do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale
Time frame: Day 1
"How helpful do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Medication Overuse
Recruiting
Greater Occipital Nerve Block for Migraine With Medication Overuse Headache
Migraine Disorders, Medication Overuse Headache
Recruiting
Efficacy and Central Mechanisms of Electroacupuncture for Medication Overuse Headache
Medication Overuse Headache, Electroacupuncture
RecruitingObservational study
China HeadAche DIsorders RegiStry
Headache Disorders, Primary, Migraine
RecruitingObservational study
i-NEED: NEw migrainE Drugs Database
Episodic Migraine, Chronic Migraine
Active, not recruiting
Prescribing Outcomes of a GP-Targeted Deprescribing Educational Intervention: A Cluster Randomized Trial
Medication Overuse, Deprescriptions
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah Vordenberg, PharmD, MPH principal investigator
University of Michigan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Additional harm information and Less information in people with Medication Overuse, run by University of Michigan at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
"How safe do you think it would be to continue taking aspirin?" measured on a 6-point Likert scale (time frame: Day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026; AzTrials last refreshed its copy on 7 Nov 2026.